ADMA Biologics (NASDAQ:ADMA) Upgraded to Strong-Buy at Zacks Research

ADMA Biologics (NASDAQ:ADMA) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Wall Street Zen upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday. Two analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $32.00.

ADMA Biologics Price Performance

ADMA stock opened at $16.38 on Monday. The stock has a market cap of $3.90 billion, a price-to-earnings ratio of 27.30 and a beta of 0.51. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The company has a 50 day simple moving average of $17.13 and a 200 day simple moving average of $16.80. ADMA Biologics has a 1 year low of $13.50 and a 1 year high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.20. The firm had revenue of $139.16 million for the quarter, compared to analysts’ expectations of $139.80 million. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The company’s revenue was up 18.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.46 earnings per share. Research analysts anticipate that ADMA Biologics will post 0.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada increased its stake in shares of ADMA Biologics by 112.7% in the first quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock valued at $1,903,000 after buying an additional 50,801 shares during the period. Ashton Thomas Private Wealth LLC bought a new stake in ADMA Biologics in the first quarter valued at approximately $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in ADMA Biologics by 59.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock valued at $16,201,000 after purchasing an additional 305,064 shares during the period. Envestnet Asset Management Inc. increased its position in ADMA Biologics by 108.5% during the 2nd quarter. Envestnet Asset Management Inc. now owns 143,229 shares of the biotechnology company’s stock valued at $2,608,000 after purchasing an additional 74,543 shares during the period. Finally, Amalgamated Bank raised its holdings in ADMA Biologics by 0.8% during the 2nd quarter. Amalgamated Bank now owns 67,665 shares of the biotechnology company’s stock worth $1,232,000 after purchasing an additional 540 shares during the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.